Xenon Pharmaceuticals, Inc engages in discovering and developing therapeutics to improve the lives of patients with neurological disorders. It focuses on the treatment of epilepsy. Its products include XEN496, XEN1101, XEN901, and XEN007. The company was founded by Simon Neil Pimstone, Johannes J. P. Kastelein, and Michael R. Hayden on November 5, 1996 and is headquartered in Burnaby, Canada.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone604-484-3300
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$310,000.00
Profitability
Miscellaneous
Employees89
Next Earnings Date3/4/2020 (Estimated)
OptionableOptionable
Xenon Pharmaceuticals (NASDAQ:XENE) Frequently Asked Questions
What is Xenon Pharmaceuticals' stock symbol?
Xenon Pharmaceuticals trades on the NASDAQ under the ticker symbol "XENE."
How were Xenon Pharmaceuticals' earnings last quarter?
Xenon Pharmaceuticals Inc (NASDAQ:XENE) announced its quarterly earnings data on Tuesday, November, 5th. The biopharmaceutical company reported ($0.33) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.49) by $0.16. The biopharmaceutical company earned $3.50 million during the quarter. View Xenon Pharmaceuticals' Earnings History.
When is Xenon Pharmaceuticals' next earnings date?
What price target have analysts set for XENE?
2 equities research analysts have issued 1-year price targets for Xenon Pharmaceuticals' stock. Their forecasts range from $18.00 to $25.00. On average, they anticipate Xenon Pharmaceuticals' share price to reach $21.50 in the next twelve months. This suggests a possible upside of 138.9% from the stock's current price. View Analyst Price Targets for Xenon Pharmaceuticals.
What is the consensus analysts' recommendation for Xenon Pharmaceuticals?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Xenon Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Xenon Pharmaceuticals.
Has Xenon Pharmaceuticals been receiving favorable news coverage?
News articles about XENE stock have been trending very negative on Tuesday, InfoTrie reports. InfoTrie identifies positive and negative press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Xenon Pharmaceuticals earned a news sentiment score of -3.2 on InfoTrie's scale. They also assigned press coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the stock's share price in the near term. View News Stories for Xenon Pharmaceuticals.
Are investors shorting Xenon Pharmaceuticals?
Xenon Pharmaceuticals saw a increase in short interest in October. As of October 31st, there was short interest totalling 488,600 shares, an increase of 75.8% from the September 30th total of 277,900 shares. Based on an average daily trading volume, of 48,400 shares, the days-to-cover ratio is currently 10.1 days. Currently, 2.2% of the shares of the stock are sold short. View Xenon Pharmaceuticals' Current Options Chain.
Who are some of Xenon Pharmaceuticals' key competitors?
Some companies that are related to Xenon Pharmaceuticals include ArQule (ARQL), Karyopharm Therapeutics (KPTI), Athenex (ATNX), Achillion Pharmaceuticals (ACHN), G1 Therapeutics (GTHX), Axsome Therapeutics (AXSM), Amphastar Pharmaceuticals (AMPH), Eagle Pharmaceuticals (EGRX), Arvinas (ARVN), Cara Therapeutics (CARA), Rocket Pharmaceuticals (RCKT), Amneal Pharmaceuticals (AMRX), Dova Pharmaceuticals (DOVA), ZIOPHARM Oncology (ZIOP) and Constellation Pharmaceuticals (CNST).
What other stocks do shareholders of Xenon Pharmaceuticals own?
Who are Xenon Pharmaceuticals' key executives?
Xenon Pharmaceuticals' management team includes the folowing people:
- Simon Neil Pimstone, Chief Executive Officer & Director
- Ian C. Mortimer, President, Chief Financial Officer & Secretary
- Ernesto Aycardi, Chief Medical Officer
- Robin Sherrington, Executive VP-Business & Corporate Development
- Charles J. Cohen, Vice President-Biological Sciences
Who are Xenon Pharmaceuticals' major shareholders?
Xenon Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include NEA Management Company LLC (2.34%), Granite Point Capital Management L.P. (1.15%), California Public Employees Retirement System (0.24%), Alps Advisors Inc. (0.20%), Russell Investments Group Ltd. (0.14%) and Supplemental Annuity Collective Trust of NJ (0.04%). Company insiders that own Xenon Pharmaceuticals stock include Frank A Holler, Mohammad Azab and Simon N Pimstone. View Institutional Ownership Trends for Xenon Pharmaceuticals.
Which institutional investors are selling Xenon Pharmaceuticals stock?
XENE stock was sold by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Granite Point Capital Management L.P. and Alps Advisors Inc.. Company insiders that have sold Xenon Pharmaceuticals company stock in the last year include Frank A Holler, Mohammad Azab and Simon N Pimstone. View Insider Buying and Selling for Xenon Pharmaceuticals.
Which institutional investors are buying Xenon Pharmaceuticals stock?
XENE stock was purchased by a variety of institutional investors in the last quarter, including NEA Management Company LLC, Supplemental Annuity Collective Trust of NJ, California Public Employees Retirement System and Tower Research Capital LLC TRC . View Insider Buying and Selling for Xenon Pharmaceuticals.
How do I buy shares of Xenon Pharmaceuticals?
Shares of XENE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Xenon Pharmaceuticals' stock price today?
One share of XENE stock can currently be purchased for approximately $9.00.
How big of a company is Xenon Pharmaceuticals?
Xenon Pharmaceuticals has a market capitalization of $232.83 million and generates $310,000.00 in revenue each year. The biopharmaceutical company earns $-34,500,000.00 in net income (profit) each year or ($1.33) on an earnings per share basis. Xenon Pharmaceuticals employs 89 workers across the globe.View Additional Information About Xenon Pharmaceuticals.
What is Xenon Pharmaceuticals' official website?
How can I contact Xenon Pharmaceuticals?
Xenon Pharmaceuticals' mailing address is 200 - 3650 GILMORE WAY, BURNABY A1, V5G 48W. The biopharmaceutical company can be reached via phone at 604-484-3300 or via email at [email protected]
MarketBeat Community Rating for Xenon Pharmaceuticals (NASDAQ XENE)
MarketBeat's community ratings are surveys of what our community members think about Xenon Pharmaceuticals and other stocks. Vote "Outperform" if you believe XENE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe XENE will underperform the S&P 500 over the long term. You may vote once every thirty days.
